Darifenacin, an M3 Selective Receptor Antagonist, is an Effective and Well-Tolerated Once-Daily Treatment for Overactive Bladder
- 1 April 2004
- journal article
- clinical trial
- Published by Elsevier in European Urology
- Vol. 45 (4) , 420-429
- https://doi.org/10.1016/j.eururo.2004.01.008
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- 513 Darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderly volunteersEuropean Urology Supplements, 2004
- Urodynamic Effect of Acute Transcutaneous Posterior Tibial Nerve Stimulation in Overactive BladderJournal of Urology, 2003
- M3 muscarinic receptors mediate contraction of human urinary bladderBritish Journal of Pharmacology, 2002
- The overactive bladderBJU International, 2001
- Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscleBritish Journal of Pharmacology, 2001
- Dry mouth with conventional and controlled-release oxybutynin in urinary incontinenceObstetrics & Gynecology, 2000
- Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinenceUrology, 1999
- ONCE DAILY CONTROLLED VERSUS IMMEDIATE RELEASE OXYBUTYNIN CHLORIDE FOR URGE URINARY INCONTINENCEJournal of Urology, 1999
- Efficacy and safety of tolterodine in patients with detrusor instability: a dose‐ranging studyBritish Journal of Urology, 1998
- A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder complianceBJOG: An International Journal of Obstetrics and Gynaecology, 1997